FLT3内部串联重复残留病灶对急性髓系白血病的预后价值
在161例新诊断FLT3-ITD急性髓系白血病患者中,于诊断时及强化诱导缓解后完全缓解时行二代测序检测FLT3-ITD残留病灶,47例(29%)可检出残留病灶;该残留病灶与更高的4年累积复发率(75%对33%,P<.001)和更差的4年总生存(31%对57%,P<.001)相关,多因素分析中为复发和总生存的独立预后因素。
要点
- 完全缓解时二代测序检出FLT3-ITD残留病灶者4年累积复发率75%,未检出者33%(P<.001)。
- FLT3-ITD残留病灶阳性者4年总生存31%,阴性者57%(P<.001)。
- 多因素分析中FLT3-ITD残留病灶为复发(风险比3.55,P<.001)和总生存(风险比2.51,P=.002)的独立预后因素。
核心结论
- 完全缓解时基于二代测序检出FLT3-ITD残留病灶,可识别出复发和死亡风险很高的急性髓系白血病患者,其预后意义超过诊断时大多数公认的预后因素及治疗中的其他残留病灶检测。
- 作者认为该结果支持FLT3-ITD作为急性髓系白血病动态疾病风险评估的临床相关生物标志物。
研究设计与样本
- 在161例新诊断FLT3-ITD急性髓系白血病患者中,于诊断时及强化诱导缓解治疗后完全缓解时行二代测序检测。
- 将FLT3-ITD残留病灶状态与累积复发率和总生存进行相关性分析。
主要发现
- 161例患者中47例(29%)可检出基于二代测序的FLT3-ITD残留病灶。
- FLT3-ITD残留病灶阳性者4年累积复发率为75%,阴性者为33%(P<.001)。
- FLT3-ITD残留病灶阳性者4年总生存为31%,阴性者为57%(P<.001)。
- 多因素分析中,完全缓解时检出FLT3-ITD残留病灶对复发具有独立预后意义(风险比3.55,P<.001),对总生存亦具有独立预后意义(风险比2.51,P=.002)。
- FLT3-ITD残留病灶的预后价值超过大多数公认的临床和分子预后因素,包括诊断时FLT3-ITD等位基因比值以及基于二代测序的突变NPM1检测或多参数流式细胞术的残留病灶评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of FLT3-ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)-based FLT3-ITD MRD detection on treatment outcome in a cohort of patients with newly diagnosed AML in relation to established prognostic factors at diagnosis and other MRD measurements, ie, mutant NPM1 and multiparameter flow cytometry. METHODS: In 161 patients with de novo FLT3-ITD AML, NGS was performed at diagnosis and in CR after intensive remission induction treatment. FLT3-ITD MRD status was correlated with the cumulative incidence of relapse and overall survival (OS). RESULTS: NGS-based FLT3-ITD MRD was present in 47 of 161 (29%) patients with AML. Presence of FLT3-ITD MRD was associated with increased risk of relapse (4-year cumulative incidence of relapse, 75% FLT3-ITD MRD v 33% no FLT3-ITD MRD; P < .001) and inferior OS (4-year OS, 31% FLT3-ITD MRD v 57% no FLT3-ITD MRD; P < .001). In multivariate analysis, detection of FLT3-ITD MRD in CR confers independent prognostic significance for relapse (hazard ratio, 3.55; P < .001) and OS (hazard ratio 2.51; P = .002). Strikingly, FLT3-ITD MRD exceeds the prognostic value of most generally accepted clinical and molecular prognostic factors, including the FLT3-ITD allelic ratio at diagnosis and MRD assessment by NGS-based mutant NPM1 detection or multiparameter flow cytometry. CONCLUSION: NGS-based detection of FLT3-ITD MRD in CR identifies patients with AML with profound risk of relapse and death that outcompetes the significance of most established prognostic factors at diagnosis and during therapy, and furnishes support for FLT3-ITD as a clinically relevant biomarker for dynamic disease risk assessment in AML.
引用
- Grob T, Sanders MA, Vonk CM, et al. Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. J Clin Oncol. 2022. PMID: 36315929. doi:10.1200/JCO.22.00715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。